Profils des marqueurs sériques maternels de la trisomie 21 : révision des commentaires et des conduites à tenir

Le résumé fourni par la source

In France, for the vast majority of patients, screening for Down syndrome using circulating cell-free fetal DNA is contingent upon prior assessment of maternal serum markers and calculation of a specific risk estimate for this aneuploidy. Certain marker profiles may also suggest other fetal or maternal pathologies. This article therefore aims: (i) to clarify and explain any comments that may appear in laboratory reports; (ii) to propose a clinical interpretation and a procedure to be followed for the monitoring of the considered pregnancy. It updates a first article published in 2014 and, like its predecessor, reflects broad consensus among the biologists authorised to perform this screening.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.